Clinical Trials Logo

Clinical Trial Summary

A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positive tumors . In this single-arm, open-label, one center, dose escalation clinical study, the main purpose is to determine the safety and efficacy of infusion of autologous Chimeric Switch Receptor modified T cells (CSR T) in adult patients with PD-L1 positive, recurrent or metastatic malignant tumors.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Metastatic PD-L1+ Malignant Tumors
  • Neoplasms
  • Recurrent PD-L1+ Malignant Tumors

NCT number NCT02930967
Study type Interventional
Source China Meitan General Hospital
Contact Shidong Wei, MD
Phone +86-13146634751
Email liqinghe9644679@163.com
Status Recruiting
Phase Phase 1
Start date August 2016
Completion date August 2019